Thank you for your patience during the peer-review of your study at EMBO reports. We have now received the three enclosed reports on it and circulated the (anonymous) comments to all three referees for their feedback. As you will see, although referee 3 is more positive, referees 1 and 2 are not supportive of publication of the study in EMBO reports. Both consider the overall conceptual novelty of the findings rather limited, and all three referees note that the link to psoriasis, which is the most novel and attractive aspect of the study, is too preliminary for consideration here.
Thank you for your patience during the peer-review of your study at EMBO reports. We have now received the three enclosed reports on it and circulated the (anonymous) comments to all three referees for their feedback. As you will see, although referee 3 is more positive, referees 1 and 2 are not supportive of publication of the study in EMBO reports. Both consider the overall conceptual novelty of the findings rather limited, and all three referees note that the link to psoriasis, which is the most novel and attractive aspect of the study, is too preliminary for consideration here.
Given these opinions, we feel it would not be productive to invite revision of your study. We would be open, however, to considering the resubmission of a related study, if you were to considerably strengthen the psoriasis aspect of the work, in addition to addressing the other referee concerns.
I am sorry convey disappointing news, and hope that the referee comments are helpful in your continued work in this area.
REFEREE REPORTS
Referee #1:
The CARD11 (CARMA1) homolog CARD14 (CARMA2) is a putative signaling adaptor in keratinocytes with a role in psoriasis. In the present manuscript Afonina et. al show that CARD14 physically and functionally interacts with the paracaspase MALT1. The authors demonstrate enhanced NF-kB, JNK and p38 activation after overexpression of CARD14, which depends on the presence of MALT1. Moreover, they show that CARD14 expression induces MALT1 cleavage activity and show that a small-molecule MALT1 inhibitor inhibits CARD14-induced gene expression.
The manuscript shows some new aspects about the interaction of CARD14 and MALT1 and its impact on downstream signaling events. The study confirms previous analyses that a short CARD14 variant activates NF-kB and extends this by also showing effects on MAPK activation and MALT1 protease activation. Also, a stronger effect of full length CARD14 is shown, but it is often not clear if CARD14 FL or CARD14sh was used. The basic findings have been published before and all experiments rely on CARD14 overexpression in HEK293T cells. Thus, the physiological relevance of the findings is unclear and the manuscript does not add significant new insights. It would be important to know in which pathway CARD14 is implicated in keratinocytes and if this is relevant for psoriasis. There are many mistakes in the figures and text and not everything could be listed.
Major specific points:
Fig. 1: C) The impact of CARD14 overexpression on phospho-JNK and phospho-p38 is quite weak, also compared to Fig. 3B . 3B was most likely done with the short form, so given the slightly higher expression FL CARD14, it seems that FL CARD14 does not really activate JNK and p38. ERK activation is a critical factor for keratinocyte proliferation and should be analyzed. The positive controls TRAF6 and the constitutive active CARD11 mutant are missing in the figure, although they were mentioned in the text. The effects of A20 and CYLD on NF-kB upon overexpression of CARD14 are interesting, but given the broad spectrum of these DUBs quite expected. In the absence of any signaling pathway, would it be possible to show that psoriasis-associated CYLD/A20 mutants are acting in a different way on CARD14-mediated signaling? Fig. 3 : A) Does MALT1 interact with CARD14 directly in the absence of BCL10? I suppose this is CARD14sh. It would be interesting to compare CBM-complex formation between CARD14sh, CARD14 FL, CARD11 (with MAGUK) and CARD9 (w/o MAGUK) to see if there are differences. B) Why are the effects so much stronger than in Fig.1C . Given the very weak expression of CARD11, the effects are much stronger when compared to CARD14. Also given the slightly different expression of CARD14, the impact of MALT1 expression on MAPK activation is rather mild. What is the effect of the MALT1 C/A mutant? C and D) It is not clear why only the mutants are co-regulated by MALT1. Is there an increased interaction between MALT1 and CARD14 mutants due to enhanced BCL10 binding? Mutant H171N is not explained. NF-kB signaling should be analyzed in greater detail, e.g. IKK activation, IkBa degradation. Labeling of Western Blots is missing. Fig. 4 : B) Given the stronger expression of CARD14 in MALT1 overexpressing cells, the augmented of JNK activation is questionable. Similar expression is achieved with 30 and 7.5 ng and in these lanes pJNK and pJun is quite comparable. Apparently CARD11 expression failed in the experiment. C) It would be more relevant to analyze downstream signaling pathways in HaCaT. In absence of any stimulus the physiological relevance is unclear. CARD11, BCL10 and MALT1 are critical regulators of NF-kB activation in lymphocytes. Upon antigen receptor triggering, these three proteins form a complex, which acts on the one hand as a scaffold platform to recruit regulators of NF-kB and JNK activation, on the other hand the complex is needed for the activation of MALT1 protease activity, which cleaves multiple substrates important for lymphocyte activation. In the present study by Afonina et al., CARD14 was identified as upstream regulator of BCL10 and MALT1. Overexpression of CARD14 was sufficient to recruit BCL10 and MALT1 and thus to activate NF-kB. Furthermore, the study shows that JNK and p38 phosphorylation can be induced by CARD14 overexpression. Similar to CARD11, CARD14 was able to induce MALT1 protease activity, which has been previously suggested as a drug target in autoimmune diseases. Because CARD14 mutations have been described in psoriasis patients, CARD14 function in keratinocytes is of special interest. Indeed, CARD14 expression in HaCaT cells induced IL-8 and MCP-1 secretion, which could be strongly decreased by MALT1 silencing or a MALT1 protease inhibitor. Thus, the study by Afonina et al. provides evidence that MALT1 might be a valuable therapeutic target in psoriasis. The manuscript is written in a logical order and it is easy to follow the experiments. The claims are well supported by the experiments, which are overall of high quality, but the novelty of the findings is rather limited, and most of the experiments are performed in 293T cells. That CARD14 has a similar role as CARD11 in NF-kB activation, and that CARD14 overexpression can induce NF-kB activity and binds BCL10 has been published previously (Jordan et al. We have the following major concerns: 1) To strengthen the hypothesis of the authors that MALT1 could be a relevant target in psoriasis, the authors must investigate whether the CARD14 mutants found in psoriasis samples can indeed drive MALT1 protease activity 2) To increase the relevance of the paper, the authors must perform experiments with primary human or mouse keratinocytes that can be transfected with wt CARD14 and its mutants, and assess NF-kB activation and expression of relevant cytokines or chemokines in this setting Minor concerns: 1) In Fig. 3B the authors show a synergy between CARD14 and MALT1 with respect to c-Jun stabilization and the phosphorylation of JNK and p38. Similar experiments should be performed with CARD14 and BCL10 to demonstrate the importance of BCL10 in bridging CARD14 and MALT1. 2) In Figure 5D , the authors show the effect of the MALT1 inhibitor Mepazine on IL-8 and MCP-1 secretion. Which concentration of mepazine was used for this assay? To exclude toxic effects of this inhibitor on HaCaT cells, a viability assay should be performed. Alternatively, the unaltered TNF induced IL-8 and MCP-1 secretion in presence of Mepazine, which is mentioned in the text but not shown as a figure, could be included in Figure 5D . 3) Because CARD14 overexpression led to the phosphorylation of JNK and p38, the authors should discuss the phenotype of CARD11, BCL10 and MALT1 KO mice with respect to p38 and JNK activation. 4) The authors claim that NF-kB-dependent reporter gene expression is not altered by an inactive MALT1 protease compared to wild-type MALT1 and state "data not shown". This is surprising, since previous publications including work from the authors clearly has demonstrated defects in NFkB reporter assays when an inactive MALT1 protease or IAP2-MALT1 construct is expressed (e.g. Uren et al., 2000; Coornaert et al., 2008) . The authors show the original data or discuss this point. 5) Figure 3D shows a CARD14 mutant (H171N) that is not mentioned nor discussed in the text. Little is known about CARD14 function, despite it being identified as a psoriasis susceptibility gene. The authors delightfully show interactions for CARD14 in both HEK293T cells and HaCaTs demonstrating its ability to not only activate NFkB but also p38, JNK, c-Jun and that these pathways are further activated in the presence of MALT1 -a protein that co-IPs with CARD14. The biochemistry and signaling work is elegantly done and well controlled. The figure demonstrating that MALT1 inhibition leads to suppression of IL-8 and MCP is novel. It will be exciting to see where this work moves forward.
Several minor things need to be addressed and are listed below.
1. CARD14 and/or MALT1 targeting in keratinocytes (KCs) -is unlikely to serve as a target for psoriasis due to the levels of inhibition targeting so many activated cells and it being effective is low. However -if it has the ability to interfere with KC-Immune cell interactions -and that CARD14 signaling is similar in immune cells, in particular T cells would add significantly to the field. The authors may want to soften this statement.
Figure 1
The authors present NFkB and IL-8 secretion in HEK293T cells. Strength would be added if they showed a more "psoriasis-like" cytokine from this assay -that is also derived from HEK cellssomething that would also be derived from KCs -that we know is important to psoriasis -perhaps one of the IL-36 family members known to contribute to psoriasis pathogenesis?
Where are the TRAF6 and CARD11 data that are mentioned? Could they also examine phospho-Jun too? P63 p73? Are these sub-units not also downstream of JNK and p38?
In Figure 1C does the short CARD14sh actually elicit more phosphoJNK? But not p38? What is the significance of this?
What is it about full length vs the short version of CARD14 that seems to lead to so much increased activity. The CARD14 mutants in the presence of MALT1 also have striking increases in NFKB; can they add some level of discussion about this?
Strength to the paper is their inclusion of taking their initial findings in HEK293T cells and moving into HaCaTs. Again it would be nice to see them stimulate their dox inducible CARD14 cells and examine a psoriasis specific downstream transcript of protein from CARD14 -other than IL-8 and MCP1 -something more "psoriasis-like" (see above) -S100A8/A9, IL-36 family members, IL-17C -the authros should look at the Chiricozzi et al. Journal of Investigative Dermatology paper and identify several target transcripts that are directly relevant to psoriasis that are derived from KCs that may be outcomes measures they could also include.
Resubmission 26 January 2016
We would like to thank the editor and the reviewers for evaluating our manuscript and providing constructive comments, which helped us to improve the manuscript. In our revised manuscript we have strengthened the link to psoriasis by extending our observations to human primary keratinocytes, relevant psoriasis-associated CARD14 mutants and psoriasis-associated cytokine and chemokine readouts. More specifically, we show that CARD14 physically interacts with paracaspase MALT1 and activates MALT1 proteolytic activity and inflammatory gene expression, which are enhanced by psoriasis-associated CARD14 mutations. Moreover, we show that MALT1 deficiency or pharmacological inhibition of MALT1 catalytic activity inhibit pathogenic mutant CARD14-induced cytokine and chemokine expression in human primary keratinocytes. In addition we have addressed all other concerns from the reviewers. A point-by point response to the referee's comments is provided below. Figure 2B . Figure  1) . Figure 2C . 
Following the reviewer's suggestion we have also investigated the effect of CARD14 expression on the ERK pathway and found that CARD14 has no effect on ERK activation (Supplementary

We apologize for not being more clear and we indeed used shCARD14 in the experiment that is shown (now indicated in the revised figure 2A). Although we did not perform immunoprecipitation experiments in cells lacking BCL10, it is very unlikely that CARD14 interacts directly with MALT1. This is based on the comparison with other CARD family members that form a CBM complex, all of which use BCL10 (via CARD-CARD domain interactions) as an adaptor to interact with MALT1 (which is known to bind constitutively to BCL10 in the cell
We thank the reviewer for this excellent comment. Following the reviewer's suggestion, we have performed a co-immunoprecipitation experiment comparing the interaction of MALT1 with wildtype CARD14, mutant CARD14(E138A) (which is MALT1-dependent and the mutation that most potently affects CARD14 activity) and mutant CARD14(H174N) (which is not MALT1-dependent and, in contrast to other CARD14 mutants, was previously shown to require an extra stimulus to activate NF-κB; now explained in the revised text). This novel experiment shows that the CARD14(E138A) mutant also displays enhanced coimmunoprecipitation with MALT1, as compared to wild-type and CARD14(H171N) (Figure 2D). These new data suggest that an increased interaction between MALT1 and CARD14(E138A) could explain the increased bioactivity and MALT1dependency of psoriasis-associated CARD14 mutants. Labeling of the western blot has been completed (revised figure 2C).
Following the reviewer's suggestion, we have also compared the ability of different CARD14 mutants to activate IKK-dependent IκBα phosphorylation, as well as activation of MALT1 proteolytic activity (Figure 4D). Importantly, the MALT1-dependent mutants (G117S, E138A and E142K), but not H171N, are also more potent activators of IKK and MALT1 proteolytic activity, which is in agreement with the other data shown in
As mentioned above, this figure has been replaced with a new figure 3B, clearly illustrating the MALT1 dependency of CARD14-induced JNK activation.
C) It would be more relevant to analyze downstream signaling pathways in HaCaT. In absence of any stimulus the physiological relevance is unclear.
We have performed several additional experiments in human primary keratinocytes showing: 1. Mutant CARD14 induced expression of several cytokines and chemokines, and the effect of MALT1 silencing; 2. IL-8 induction by different CARD14 mutants + effect MALT1 silencing or protease inhibition; 3. A20 cleavage by different CARD14 mutants + effect MALT1 protease inhibition (Figure 6 in revised manuscript).
Fig. 5: C) Does the difference in MALT1 dependent CYLD cleavage upon CARD14 overexpression impact on JNK signaling as has been suggested for TCR signaling through CARD11?
CARD14 was still able to activate JNK in cells expressing protease dead MALT1 ( Figure 3B ), excluding a role for CYLD cleavage in JNK activation in keratinocytes. However, we cannot exclude a role of CYLD cleavage in other CARD14 effects. This is also discussed in the text of the revised manuscript. Figure 6D ).
D) The authors should determine, if CARD14 induces MALT1 activity in HaCaT and if that is inhibited by the MALT1 inhibitor.
We already showed in our original manuscript that CARD14 induces IL-8 and MCP-1 expression in HaCaT cells that could be inhibited by MALT1 silencing or MALT1 inhibitor. We have now extended these findings to primary keratinocytes (Figure 6; see also above), including the demonstration that CARD14 induces A20 cleavage in primary human keratinocytes, which can be inhibited by mepazine (
Referee #2:
We thank this reviewer for finding our study of special interest, the manuscript being well written and commenting on the high quality of our experiments. We note the reviewer's general comment that the novelty is rather limited and most of the experiments are performed in 293T cells. It is mentioned by the reviewer that it has been published previously that CARD14 has a similar role as CARD11 in NF-kB activation, and that CARD14 overexpression can induce NF-kB activity and binds BCL10 Figures 4D and 6D) .
2) To increase the relevance of the paper, the authors must perform experiments with primary human or mouse keratinocytes that can be transfected with wt CARD14 and its mutants, and assess NF-kB activation and expression of relevant cytokines or chemokines in this setting
We agree that this kind of experiments would improve the physiological relevance of our findings and have now performed several experiments on human primary keratinocytes (new Figure 6), showing that MALT1 deficiency or pharmacological inhibition of MALT1 catalytic activity inhibit pathogenic mutant CARD14-induced cytokine and chemokine expression, as well as A20 cleavage in human primary keratinocytes.
Minor concerns: 1) In Fig. 3B the authors show a synergy between CARD14 and MALT1 with respect to c-Jun stabilization and the phosphorylation of JNK and p38. Similar experiments should be performed with CARD14 and BCL10 to demonstrate the importance of BCL10 in bridging CARD14 and MALT1. Because MALT1 the effect of MALT1 co-expression on CARD14-induced JNK activation was rather mild (see also the comment of reviewer 1 and our reply above), we thought a similar experiment with BCL10 would not be very informative. Instead we tested the effect of BCL10 knockdown on CARD14induced NF-kB activation, showing the important role of BCL10 in CARD14induced signaling (Supplementary Figure 2A) . In this context and in response to reviewer 1, we also compared CBM complex formation of CARD14 with other CARD family proteins (Supplementary Figure 2B) . Figure 5D , the authors show the effect of the MALT1 inhibitor Mepazine on IL-8 and MCP-1 secretion. Which concentration of mepazine was used for this assay? To exclude toxic effects of this inhibitor on HaCaT cells, a viability assay should be performed. Alternatively, the unaltered TNF induced IL-8 and MCP-1 secretion in presence of Mepazine, which is mentioned in the text but not shown as a figure, could be included in Figure 5D .
2) In
Three different concentrations of mepazine were used as indicated at the bottom of the figure ( Figure 4E in the revised manuscript) . We now also included the TNF data in this figure. 3) Because CARD14 overexpression led to the phosphorylation of JNK and p38, the authors should discuss the phenotype of CARD11, BCL10 and MALT1 KO mice with respect to p38 and JNK activation.
The comparison with CARD11 signaling has now been mentioned in the discussion. 
4) The authors claim that NF-kB-dependent reporter gene expression is not altered by an
Supplementary figure 3 now shows these data. Previously published data (including Uren et al and Coornaert et al) only showed defects in NF-kB reporter assays when inactive API2/MALT was used.
These findings are also extensively discussed in the discussion of the revised manuscript. Figure 3D shows a CARD14 mutant (H171N) that is not mentioned nor discussed in the text.
5)
We apologize for this. The previously published effect of this mutant on CARD14 signaling is now mentioned in the revised manuscript. We apologize for these mistakes, which have been corrected in the revised manuscript. This has been corrected.
Referee #3:
We are happy to read that this reviewer finds that the biochemistry and signaling work is elegantly done and well controlled.
Several minor things need to be addressed and are listed below. Where are the TRAF6 and CARD11 data that are mentioned? Could they also examine. Are these sub-units not also downstream of JNK and p38? In Figure 1C does the short CARD14sh actually elicit more phosphoJNK? But not p38? What is the significance of this?
CARD14 and/or MALT1 targeting in keratinocytes (
We apologize for this mistake. TRAF6 and CARD11 are shown in Figure 2B . What is it about full length vs the short version of CARD14 that seems to lead to so much increased activity. The CARD14 mutants in the presence of MALT1 also have striking increases in NFKB; can they add some level of discussion about this?
As mentioned above and also in our reply to reviewer 1, we have carefully analyzed differences between CARD14 and CARD14sh in their ability to activate NF-kB, p38 and JNK. Taking into account slight differences in their expression levels, we have to conclude that CARD14 and CARD14sh activate NF-kB, p38, JNK and IL-8 expression with largely equal efficiency. This has been corrected in the revised manuscript. The CARD14 mutants however do have increased NF-kB and MALT1 proteolytic activation potential compared to wild type CARD14, which is most pronounced upon MALT1 co-transfection ( Figures 2C and 4D in the revised manuscript). This is shown to be associated with the increased ability of CARD14 to interact with MALT1 ( Figure 2D ). These novel data are also discussed in the revised manuscript. Thank you for the submission of your research manuscript to EMBO reports. We have now received the enclosed report on it. As you will see, referee#2 now finds the manuscript suitable for publication in EMBO reports. Referee #3 already supported the previous version of the manuscript, provided his/her points will be addressed, which you did in your revision. Referee #1 was not able to review the paper again, but your response to his/her points have been evaluated positively by referee #2. Referee #2 has nevertheless raised some further minor points. I would therefore like to ask you for a minor revision of your manuscript addressing all referee points, before we can proceed with the formal acceptance of your study.
Supplementary/additional data: The Expanded View format, which will be displayed in the main HTML of the paper in a collapsible format, has replaced the Supplementary information. You can submit up to 5 images as Expanded View. Please follow the nomenclature Figure EV1 , Figure EV2 etc. The figure legend for these should be included in the main manuscript document file in a section called Expanded View Figure Regarding data quantification and statistics, can you please specify the number "n" for how many experiments were performed, the bars and error bars (e.g. SEM, SD) and the test used to calculate pvalues in the respective figure legends? This information must be provided in the figure legends. Please also include scale bars in all microscopy images.
We now strongly encourage the publication of original source data with the aim of making primary data more accessible and transparent to the reader. The source data will be published in a separate source data file online along with the accepted manuscript and will be linked to the relevant figure.
If you would like to use this opportunity, please submit the source data (for example scans of entire gels or blots, data points of graphs in an excel sheet, additional images, etc.) of your key experiments together with the revised manuscript. Please include size markers for scans of entire gels, label the scans with figure and panel number, and send one PDF file per figure or per figure panel.
I look forward to seeing a revised version of your manuscript when it is ready. Please let me know if you have questions or comments regarding the revision.
REFEREE REPORTS
Referee #2:
The manuscript has been significantly improved by the revisions. Especially the use of primary keratinocytes and the cytokine arrays ( Figure 6 ) have strengthened the claims for a functionally important CARD14-MALT1 interaction.
We only have minor suggestions to improve the manuscript further:
-Since Supplementary Figure 4 (A20 inhibits CARD14-induced NF-κB activation through its ZnF domains) is a very interesting finding, we suggest to include it to the main figures (e.g. into Figure  5) -Even if it is described in the figure legend, the labelling of Figure 3A should be changed. As it is, the labelling suggests the use of CARD11 wt, but CARD11 L232I was expressed in this experiment.
-We think that the experiment in Supplementary Figure 3 does not add new insights to the manuscript. Since the MALT1 inhibitor has an important role in keratinocytes, it is rather confusing and unclear why MALT1 protease activity has no role in CARD14-mediated NF-kB activation in HEK293T cells upon overexpression.
2nd Revision -authors' response 11 March 2016 We are happy to read that all 3 reviewers find our manuscript suitable for publication in EMBO Reports, with only reviewer 2 still having some minor comments to be addressed. We have changed the manuscript according to the suggestions of reviewer 2 (as detailed in the file 'response to reviewers'. We also changed the Supplementary data to the Expanded View format.
We will also be happy to submit the original source data for publication online.
Response to the reviewers:
Reviewer #1 and #3: No further changes were needed.
Reviewer #2: -Since Supplementary Figure 4 (A20 inhibits CARD14-induced NF-κB activation through its ZnF domains) is a very interesting finding, we suggest to include it to the main figures (e.g. into Figure  5 ) Reply: We have included this figure in the revised version as Figure 5D .
-Even if it is described in the figure legend, the labelling of Figure 3A should be changed. As it is, the labelling suggests the use of CARD11 wt, but CARD11 L232I was expressed in this experiment. Reply: We have changed the figure legend of Figure 3A as suggested. Since the same construct was also used in Figure 2B , we also changed it there.
-We think that the experiment in Supplementary Figure 3 does not add new insights to the manuscript. Since the MALT1 inhibitor has an important role in keratinocytes, it is rather confusing and unclear why MALT1 protease activity has no role in CARD14-mediated NF-kB activation in HEK293T cells upon overexpression. Reply: To avoid any confusion, we have removed this figure from the revised manuscript and also changed the accompanying text in the results and discussion sections in the manuscript.
3rd Editorial Decision 15 March 2016
Thank you for the submission of your revised manuscript to our editorial offices. While going through your manuscript I noted that further minor revisions are necessary before we can proceed with the formal acceptance of your manuscript.
We would require statistical tests for the data shown in Figures 1A/B, 2C , 3A/C, 4E, 5A/B/C/D, 6C/D and EV2A. Please could you add also a paragraph in the methods section describing this and mention the tests used to calculate p-values also in the respective figure legends?
We would also require a paragraph on the author contribution and a conflict of interest statement. This should show up in the manuscript main text after the methods section, together with the acknowledgements.
Please also move the figure legends and the EV figure legends to the very end of your manuscript.
